RT Journal Article
T1 Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
A1 Plazas, J Gallego
A1 Arias-Martinez, A
A1 Lecumberri, A
A1 Martínez de Castro, E
A1 Custodio, A
A1 Cano, J M
A1 Hernandez, R
A1 Montes, A F
A1 Macias, I
A1 Pieras-Lopez, A
A1 Diez, M
A1 Visa, L
A1 Tocino, R V
A1 Lago, N Martínez
A1 Limón, M L
A1 Gil, M
A1 Pimentel, P
A1 Mangas, M
A1 Granja, M
A1 Carnicero, A M
A1 Pérez, C Hernández
A1 Gonzalez, L G
A1 Jimenez-Fonseca, P
A1 Carmona-Bayonas, A
K1 gastroesophageal cancer
K1 gender
K1 sex
K1 survival
K1 toxicity
AB Recommendations for research articles include the use of the term sex when reporting biological factors and gender for identities or psychosocial or cultural factors. There is an increasing awareness of incorporating the effect of sex and gender on cancer outcomes. Thus, these types of analyses for advanced gastroesophageal adenocarcinoma are relevant. Patients with advanced gastroesophageal adenocarcinoma from the Spanish AGAMENON-SEOM registry treated with first-line combination chemotherapy were selected. Epidemiology, characteristics of the disease, treatment selection, and results were examined according to sex. This analysis included 3274 advanced gastroesophageal adenocarcinoma patients treated with combination chemotherapy between 2008 and 2021: 2313 (70.7%) men and 961 (29.3%) women. Tumors in females were more frequently HER2-negative (67.8% versus 60.8%; P  This sex analysis of patients with advanced gastroesophageal adenocarcinoma from the AGAMENON-SEOM registry receiving first-line polychemotherapy found no differences in survival. Although women had worse prognostic histopathology, metastatic disease pattern, and greater toxicity, treatment allocation and compliance were equivalent.
YR 2022
FD 2022-06-14
LK http://hdl.handle.net/10668/22218
UL http://hdl.handle.net/10668/22218
LA en
DS RISalud
RD Apr 7, 2025